Evropska unija - slovenščina - EMA (European Medicines Agency)

ceva santé animale - gensko spremenjeni rekombinantne shiga-toksin-2e antigen - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - prašiči - aktivna imunizacija pujskov od štirih dni starosti za zmanjšanje smrtnosti in kliničnih znakov edemske bolezni, ki jo povzroča shiga toksin 2e, ki ga proizvaja escherichia coli (stec). začetek imunosti: 21 dni po cepljenju. trajanje imunosti: 105 dni po cepljenju.

Evropska unija - slovenščina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastična sredstva - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

molmed spa - alogenskih t celice, gensko spremenjene z retrovirusni vektor kodiranje za skrajšani obliki ljudi nizko afiniteto živca rastni faktor receptor (Δlngfr) in herpes simplex virus timidin-kinazo (hsv-tk mut2) - hematopoietic stem cell transplantation; graft vs host disease - antineoplastična sredstva - zalmoxis je indiciran kot dodatno zdravljenje pri haploidentični hematopoetski presaditvi matičnih celic (hsct) pri odraslih bolnikih z visokim tveganjem hematoloških malignomov.

Evropska unija - slovenščina - EMA (European Medicines Agency)

rhythm pharmaceuticals netherlands b.v. - setmelanotide - debelost - preparati za zaščito proti sončenju, prehrambeni izdelki - imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed bardet biedl syndrome (bbs), loss-of-function biallelic pro-opiomelanocortin (pomc), including pcsk1, deficiency or biallelic leptin receptor (lepr) deficiency in adults and children 6 years of age and above.

Evropska unija - slovenščina - EMA (European Medicines Agency)

eigerbio europe limited - lonafarnib - progeria; laminopathies - drugi zdravljene bolezni prebavil in presnove izdelki, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.

Evropska unija - slovenščina - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - metabolizem aminokislin, vrojene napake - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - metilprednizolon - tableta - metilprednizolon 32 mg / 1 tableta - metilprednizolon

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

dr. g. mann - hipromeloza - kapljice za oko, raztopina - hipromeloza 3,2 mg / 1 ml - umetne solze in druga nevtralna zdravila

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

dr. g. mann - hipromeloza - kapljice za oko, raztopina - hipromeloza 3,2 mg / 1 ml - umetne solze in druga nevtralna zdravila